Data / Drug companies / Patheon Puerto Rico, Inc.
Patheon Puerto Rico, Inc.: 16 products in the FDA NDC directory, labeler code 55370
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Puerto Rico, Inc. (labeler code 55370) lists 16 products in the FDA National Drug Code Directory. By type: 16 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on January 1, 2025.
The request: Watch Patheon Puerto Rico, Inc. (FDA labeler code 55370): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55370
- Products in commercial distribution
- 16
- Packages
- 16
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- March 30, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 15 | 93.8% |
| Export only | 1 | 6.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 16 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 8 | 50% |
| Tablet, film coated | 4 | 25% |
| Powder | 3 | 18.8% |
| Tablet, extended release | 1 | 6.2% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Empagliflozin and metformin hydrochloride | 55370-825 | Tablet | Drugs for further processing | January 1, 2025 |
| Metformin hydrochloride | 55370-824 | Powder | Drugs for further processing | August 27, 2016 |
| Metformin hydrochloride | 55370-827 | Powder | Drugs for further processing | August 4, 2016 |
| Metformin hydrochloride | 55370-826 | Powder | Drugs for further processing | July 27, 2016 |
| Empagliflozin and metformin hydrochloride | 55370-823 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-800 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-799 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-797 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-796 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-795 | Tablet | Drugs for further processing | September 12, 2015 |
| Empagliflozin and metformin hydrochloride | 55370-794 | Tablet | Drugs for further processing | September 12, 2015 |
| Loratadine and pseudoephedrine sulfate | 55370-790 | Tablet, extended release | Drugs for further processing | December 1, 2009 |
| Sitagliptin and metformin hydrochloride | 55370-006 | Tablet, film coated | Export only | March 30, 2007 |
| Sitagliptin and metformin hydrochloride | 55370-003 | Tablet, film coated | Drugs for further processing | March 30, 2007 |
| Sitagliptin and metformin hydrochloride | 55370-002 | Tablet, film coated | Drugs for further processing | March 30, 2007 |
| Sitagliptin and metformin hydrochloride | 55370-001 | Tablet, film coated | Drugs for further processing | March 30, 2007 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.